Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



東北虎藥業股份有限公司

NORTHEAST TIGER PHARMACEUTICAL CO., LTD.

(A joint stock company limited company incorporated in the People's Republic of China)

(Stock Code: 08197)

TERMINATION OF SHARE TRANSFER AGREEMENT

This announcement is made by the Northeast Tiger Pharmaceutical Co., Ltd. (the "Company") pursuant to Rule 17.10 of the Rules Governing of the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules") and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 26 June 2015 (the "Announcement"). Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings defined in the Announcement.

As disclosed in the Announcement, Mr. Liu and Ms. Xu entered into the Share Transfer Agreement in relation to, among other things, the transfer of 194,194,580 domestic shares of the Company at a consideration of RMB19,419,458 (equivalent to approximately HK\$24,274,322.5) to Ms. Xu.

The Company received notice from Ms. Xu and Mr. Liu that on 1 November 2015, Ms. Xu and Mr. Liu entered into a termination agreement (the **"Termination Agreement"**), pursuant to which the parties have terminated the Share Transfer Agreement with effect from 1 November 2015. No consideration had been paid by Ms. Xu and no domestic shares of the Company had been transferred by Mr. Liu under the Share Transfer Agreement. Upon singing of the Termination Agreement, each of Ms. Xu and Mr. Liu is released and discharged from his/her obligations and liabilities under the Share Transfer Agreement.

By order of the Board Executive Director Qin Haibo Jilin, the PRC 2 November 2015

For the purpose of this announcement and illustration only, unless otherwise specified, conversion of RMB, into HK\$, is based on the approximate exchange rate of RMB1.00 to HK\$1.25. No representation is made that any amount in HK\$ or RMB could have been or could be converted at the above rate or at any other rates.

As at the date of this announcement, the Company's executive directors are Xu Dongmei, Guo Feng and Qin Haibo and the Company's independent non-executive directors are Niu Shu Min, Zhao Zhen Xing and Hui Lai Yan.

This announcement, for which the directors (the "Directors") of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules") for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at http://www.hkgem.com for at least 7 days from the day of its posting.